Enrolling less homogeneous patient groups in clinical trials while maintaining safety may lead to a more accurate description of a drug’s safety and efficacy, FDA officials wrote in an article published April 20 in the New England Journal of Medicine.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
